Lumevoq demonstrated sustained efficacy and a positive safety profile at 4 years after a one-time injection of the gene therapy in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.
The phase 3 randomized, double-masked, placebo-controlled REFLECT clinical trial included 98 patients with Leber hereditary optic neuropathy (LHON) caused by a mutated ND4 mitochondrial gene. All patients received an intravitreal injection of Lumevoq (lenadogene nolparvovec) in one eye while the second eye was randomly assigned to receive either Lumevoq (48